PK14105 has been evaluated biologically as a potential radioligand for positron emission tomography (PET) studies targeting peripheral benzodiazepine binding sites (PBBS) receptors. When administered to rats with unilaterally lesioned striata, PK14105 was observed to quickly cross the blood-brain barrier, displaying significant radioactivity retention in the lesioned striatum, in contrast to the unlesioned striatum or cerebellar vermis. Additionally, PK14105 has the capability to inhibit receptor ligands, calcium channel ligands, and co-transporters in all salivary glands.
Hydroxy bosentan (Ro 48-5033) is a primary metabolite of Bosentan (BOS) metabolized by the cytochrome P450 system in the liver, assisting BOS pharmacologically with 10%-20% activity retention.
Angiotensin I II (2-7) is a peptide that contains the amino acids 2-7 and is converted from Angiotensin I II peptide. Angiotensin is a peptide hormone that causes vasoconstriction and a subsequent increase in blood pressure. Angiotensin also stimulates th
Sdz 280 446 is one of the most active cyclopeptolide of many resistance-modifying agents in restoring rhodamine-123 retention within multidrug-resistant P388 cells.
CS-526 is a proton pump inhibitor. The inhibitory mechanism of CS-526 on H+,K+-ATPase was a competitive antagonism to the K+ binding site of H+,K+-ATPase, and it was also a reversible inhibition. CS-526 has a potent antisecretory effect on gastric acid se
Neostigmine Iodide is a parasympathic compound used as a reversible acetylcholinesterase inhibitor to improve muscle tone in patients with myasthenia gravis and in routine anesthesia to reverse the effects of non-depolarizing muscle relaxants such as rocu
Polythiazide (NSC-108161, P-2525) is used to treat fluid retention (edema) caused by a variety of causes, including congestive heart failure, severe liver disease (cirrhosis), kidney disease, or steroid or hormonal medication.
(-)-L-threo-PDMP is an enhancer of ganglioside biosynthesis. The (-)-L-threo-PDMP (1S,2S) isomer is the active stimulatory component of DL-threo-PDMP in contrast to (+)-D-threo-PDMP , which is an inhibitor of glucosylceramide synthetase. (-)-L-threo-PDMP upregulates GM3, GD3, and GQ1b synthase levels, which are glycosyltransferases involved in ganglioside biosynthesis, and increases ganglioside levels in cells. It increases neurite outgrowth and synapse formation in vitro and improves retention of a long-term memory learned prior to forebrain ischemia in rats when administered following ischemia at a dose of 40 mg/kg per day.
8(R)-HETE is biosynthesized by lipoxygenation of arachidonic acid in marine invertebrates such as gorgonian corals and starfish. Stereochemical assignment of the (R) enantiomer is based on comparison of chiral HPLC retention times to published results.
8(S)-HETE is a major lipoxygenase product in PMA-treated murine epidermis. It activates mouse keratinocyte protein kinase C with an IC50 of 100 μM. 8(S)-HETE also activates PPARα selectively at concentrations as low as 0.3 μM. Stereochemical assignment of the (S) enantiomer is based on comparison of chiral HPLC retention times to published results.
9(R)-HETE is an enantiomer which makes up 50% of (±)9-HETE . At a concentration of 300 nM, 9(R)-HETE activates RXRγ-dependent transcription 1.5 fold relative to a control. Stereochemical assignment of the (R) enantiomer is based on comparison of chiral HPLC retention times to published results.
9(S)-HETE is an enantiomer which makes up 50% of (±)9-HETE . There are no reports of 9(S)-HETE occurring as an enzymatic lipoxygenation product. Whereas 12(S)-HETE promotes adhesion of several cell lines to endothelial cell monolayes, 9(S)-HETE and other positional HETEs are without effect. Stereochemical assignment of the (S) enantiomer is based on comparison of chiral HPLC retention times to published results.